<DOC>
	<DOCNO>NCT02273544</DOCNO>
	<brief_summary>The objective study compare pharmacokinetics dipyridamole three different Asasantin ER batch ( test ) contain different amount retard lacquer exist commercial product steady state b.i.d . treatment</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Dipyridamole Three New Formulations Asasantin ER Healthy Female Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Dipyridamole</mesh_term>
	<mesh_term>Aspirin , Dipyridamole Drug Combination</mesh_term>
	<criteria>Healthy male female subject determine result screen Signed write informed consent accordance Good Clinical Practice ( GCP ) local legislation Female subject lactate . Females must use adequate contraception ( adequate contraception e.g . sterilization , IUP , oral contraceptive ) prior administration study medication , study release study . Women must negative blood pregnancy test Age &gt; = 18 &lt; = 60 year BMI &gt; =18.5 &lt; =29.9 kg/m2 ( see abbreviation formula ) Able communicate well investigator comply study requirement Laboratory value within clinically define reference range Any finding medical examination ( include blood pressure , pulse rate , electrocardiogram ) deviate normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic hormonal disorder Surgery gastrointestinal tract ( except appendectomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; 24 hour ) ( &lt; 1 month prior administration trial ) Use drug , might influence result trial , ( &lt; 10 day prior administration trial ) Participation another trial investigational drug ( &lt; 1 month prior administration ( least 10 time relevant elimination halflife ) trial ) Having prescription medication 2 week prior study drug administration counter medication 1 week prior study drug administration ( least 10 time relevant elimination halflife ) Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Alcohol abuse ( &gt; 60 g/day ) Drug abuse Use methylxanthinecontaining drink food ( coffee , tea , cola , energy drink , chocolate , etc . ) , grapefruit grapefruit juice , alcohol , green tea , tobacco &lt; 5 day prior administration study drug Blood donation loss &gt; 400 mL ( &lt; 1 month prior administration trial ) Excessive physical activity ( &lt; 5 day prior administration trial ) Any ECG value outside reference range clinical relevance include , limited QTcB &gt; 480 m QRS interval &gt; 110 ms History familial bleeding disorder Inability comply dietary regimen study centre Inability comply investigator 's instruction For Female Subjects : Pregnancy Positive pregnancy test No adequate contraception ( adequate contraception e.g . sterilization , Intrauterine Pessary ( IUP ) , oral contraceptive ) Inability maintain adequate contraception whole study period Lactation period During interval screening start drug administration tobacco caffeine restrict avoid withdrawal start medication . As relevant influence Pharmacokinetic parameter know moderate tobacco caffeine consumption allow facilitate trial participation ( 10 cigarette 3 cigar 3 pipes/day , and/or three cup coffee respectively ) . Ovarian hormone substitution oral contraception allow continue study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>